RecruitingPancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Eligible age

18+ yrs

Accepts

All genders

Locations

23 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Sponsor: Revolution Medicines, Inc.

✓ At least 18 years old and has provided informed consent.
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
✓ Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.
✓ Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.
✓ Must have completed most recent treatment within the past 12 weeks.
✓ Adequate organ function (bone marrow, liver, kidney, coagulation).
✓ Documented RAS mutation status.
✓ Able to take oral medications.

✕ Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
✕ Any conditions that may affect the ability to take or absorb study drug.
✕ Major surgery within 28 days prior to randomization.
✕ Patient is unable or unwilling to comply with protocol-required study visits or procedures.